Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Imidazo[1,2-a]pyrazine Derivatives as Dual A2A/A2B Adenosine Receptor Antagonists Enhancing Anti-PD-1 Antibody Therapy in Colorectal Cancer.

Created on 12 Nov 2026

Authors

Chaeyeon Kim, Yumi Heo, Jiyoung Choi, Jiyeong Jung, Serin Lee, Jun Chang, Heonjoo Jeon, Inah Hwang, Jinha Yu

Published in

Journal of medicinal chemistry. Volume 69. Issue 21. Pages 26528-26556. Nov 12, 2026.

Abstract

Adenosine signaling through A2A and A2B adenosine receptors (ARs) suppresses antitumor immunity and promotes tumor progression, limiting immune checkpoint blockade in microsatellite-stable colorectal cancer (CRC). Here, we identified imidazo[1,2-a]pyrazine-urea derivatives as a new chemotype of dual hA2A/hA2B AR antagonists. SAR studies revealed that 3-iodination of the core scaffold enhanced receptor affinity and functional antagonism, with 5p emerging as a representative lead. MD simulations showed that 5p can be accommodated in the orthosteric pockets of both AR subtypes through distinct binding modes, with the 3-iodo substituent occupying adjacent subpockets. Representative compounds inhibited adenosine-induced CREB phosphorylation, restored Th1 cytokine production, and increased CD4+ and CD8+ T cell infiltration. In CD73-high CRC models, 5p suppressed tumor growth and potentiated anti-PD-1 efficacy. These findings support dual A2A/A2B AR antagonism as a strategy to reprogram the adenosine-rich tumor microenvironment and improve CRC immunotherapy.

PMID:
43018607
Bibliographic data and abstract were imported from PubMed on 12 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 11
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement